The natural course of lung function decline in asbestos exposed subjects with pleural plaques and asbestosis
| Autor: | Juergen Behr, P.M. Million, M. Barnikel, H. Knoop |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine Thorax medicine.medical_specialty Vital capacity Asbestosis medicine.disease_cause Risk Assessment Gastroenterology Asbestos 03 medical and health sciences FEV1/FVC ratio 0302 clinical medicine Germany Occupational Exposure Internal medicine medicine Humans 030212 general & internal medicine Lung Aged Retrospective Studies Clinical Deterioration business.industry Interstitial lung disease Middle Aged Pleural Diseases respiratory system medicine.disease Fibrosis Respiratory Function Tests respiratory tract diseases Phenotype medicine.anatomical_structure 030228 respiratory system Disease Progression Female Lung Diseases Interstitial Tomography X-Ray Computed business Progressive disease |
| Zdroj: | Respiratory Medicine. 154:82-85 |
| ISSN: | 0954-6111 |
| DOI: | 10.1016/j.rmed.2019.06.013 |
| Popis: | While there is a good knowledge of the natural course of lung function in interstitial lung diseases (ILD) like idiopathic lung fibrosis (IPF), many ambiguities remain in patients with asbestosis. Therefore, we evaluated the change in lung function in asbestos exposed subjects with pleural plaques and asbestosis and analysed corresponding morphology of computer tomography of the thorax. Methods 93 asbestos exposed subjects with pleural plaques and asbestosis were analysed retrospectively at the Klinikum Bergmannsheil of the Ruhr-University of Bochum. Parameters of lung function were obtained at least twice and annual changes of FVC, TLC and DLCOsb were calculated. In addition, we assessed the predominant pattern in high-resolution computer tomography of the thorax (HRCT) and differentiated three phenotypes: p (pleural) –type, f (fibrosis) -type and m (mixed) –type. Results FU data are available in 56/93 (60.2%) patients. The annual deterioration (Mean ± SEM) of FVC is −31.46 ± 17.34 ml, of TLC -55.55 ± 25.67 ml, of DLCOsb −0.38 ± 0.07 mmol/min/kPa and of DLCOva −0.05 ± 0.01 mmol/min/kPa/L. A categorical change of FVC > −100 ml was found in 12/56 (21.4%) and 18/56 (32.1%) patients showed an annual loss of TLC > −100 ml. The greatest annual decline of FVC was observed in patients with the fibrotic phenotype on HRCT (−76.76 ± 66.43 ml) and the mixed phenotype (−81.52 ± 24.79 ml), while the pleural phenotype was less affected (−10.52 ± 25.07 ml). Conclusion More than 20% of our cohort have a progressive disease with an annual loss of FVC > −100 ml. Patients with the fibrotic-phenotype or mixed-phenotype on HRCT are particularly at risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect